Healthcare

TerrAscend Announces Renewal and Replenishment of $10 Million Share Repurchase Program

TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North…

4 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative…

4 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar…

4 months ago

CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test

IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic…

4 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient…

4 months ago

Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock

Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic…

4 months ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Rezdiffra is the first and only medication approved for people living with MASH in the European Union  Conditional marketing authorization is…

4 months ago

Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing…

4 months ago

REPEAT — Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) --…

4 months ago

Adia Med Expands Into Wound Care, Targeting High-Demand $25 Billion Market and Unlocking New Growth Avenues

Winter Park, Florida--(Newsfile Corp. - August 20, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company at the…

4 months ago